A comparative study to evaluate effects on HCV-RNA-PCR by current oral anti-viral therapy with Sofosbuvir and Daclatasvir in Hepatitis C patients with and without Diabetes Melitis in Pakistan by Rauf, Kashif et al.
417                                                                             Journal of Rawalpindi Medical College (JRMC); 2020; 24(4): 417-422 
Original Article 
 
A comparative study to evaluate effects on HCV-RNA-PCR 
by current oral anti-viral therapy with Sofosbuvir and 
Daclatasvir in Hepatitis C patients with and without 
Diabetes Mellitus in Pakistan 
Kashif Rauf1, Adnan Afzal2, Fawad Hussain3, Sadia Mohammad Azam Khan4, Sikander Hayat Warraich5, 
Kashif Zaheer6
1 Senior Demonstrator, Department of Biochemistry, 
Rawalpindi Medical University, Rawalpindi. 
2 Assistant Professor, Department of Medicine, 
Rai Medical College, Sargodha. 
3 Senior Demonstrator, Department of Community 
Medicine, Niazi Medical College, Sargodha. 
4 Poonch Medical College, Rawalakot, Azad Jammu and 
Kashmir. 
5 Pulmonologist, District Headquarter Hospital,  
Sargodha. 
6 Budget & Accounts Officer,  
Rawalpindi Medical University, Rawalpindi. 
Author’s Contribution 
1,4,5 Conception of study  
1,2,3,5 Experimentation/Study conduction  
1,2,3,4 Analysis/Interpretation/Discussion  
1 Manuscript Writing 
1 Critical Review 
1 Facilitation and Material analysis 
Corresponding Author 
Dr. Kashif Rauf 
Senior Demonstrator, 
Department of Biochemistry, 
Rawalpindi Medical University, Rawalpindi 
Email: kashif.rauf@rmur.edu.pk 
Article Processing 
Received:  30/1/2020 
Accepted:  22/10/2020 
Cite this Article: Rauf, K., Afzal, A., Hussain, F., 
Khan, S.M.A., Warraich, S.H., Zaheer, K. (2020). A 
comparative study to evaluate effects on HCV-RNA-
PCR by current oral anti-viral therapy (Sofosbuvir and 
Daclatasvir) in Hepatitis C patients with & without 
Diabetes Mellitus in Pakistan. Journal of Rawalpindi 
Medical College. 30 Dec. 2020; 24(4): 417-422. 
DOI:  https://doi.org/10.37939/jrmc.v24i4.1502 
    Conflict of Interest: Nil 







Objective: To compare the effects of antiviral therapy such as sofosbuvir and daclatasvir in HCV patients who 
were diagnosed by HCV-RNA PCR without Diabetes Mellitus. 
Methodology: In this cross-sectional analysis total of 100 Hepatitis c infected patients selected, Sofosbuvir plus 
Daclatasvir treatment was given for 03 months period. Different parameters were recorded such as Total Bilirubin, 
Direct Bilirubin, Indirect Bilirubin, Hb levels, Serum ALT levels, and Serum ALP level. The statistical relation of 
the mentioned variables was analyzed through SPSS version 15. 
Results: Out of a total of 100 patients, 47% (47) were males, 53% (53) were females, 44% (44) patients had a history 
of prior interferon therapy, 23% (23) patients were having low hemoglobin levels before starting treatment. Both 
groups completed oral antiviral treatment for 12 weeks and resulting data showed the equality of treatment on 
group B and group A as no decrease in hemoglobin (p=0.799), ALT normalization (p=1.000), and no rise in serum 
bilirubin (p=0.817) during 1st month of treatment was noted in both groups while the SVR noted of both groups 
also showed no significant difference to each other i.e. 92% & 94% (p=0.696). 
Conclusion:  This study concluded that Sofosbuvir/ Daclatasvir tablets oral course of antiviral therapy against 
hepatitis C infected patients for 12 weeks showed excellent results, beneficial for the patients suffering from 
diabetes mellitus along with hepatitis C infection as compared with antiviral therapy for hepatitis C infected 
patients without diabetes 









When we talk about liver cancer it is the 5th most 
common in males and 9th in females,1 alarming 
situation enhanced the burden on healthcare 
institutions due to poor prognosis of liver-related 
cancer. When we talk about the mortality rating in the 
world it comes in 3rd leading cause of cancer mortality 
in 2013 reports2. In developed countries, the 
proportion of HCV infections leads to hepatic cellular 
carcinoma and primary liver cancer.3,4 
The best strategies are applied to reduce the burden of 
hepatic cellular carcinoma to increased uptake of 
direct-acting antiviral treatment.5,6 Reig et al. studied 
showed that that direct-acting antiviral treatment 
could increase the risk of hepatic cellular carcinoma 
recurrence7 consider uncertainty direct-acting antiviral 
treatment and hepatic cellular carcinoma risk.8,9 
Previously meta-analysis estimated the level of risk 
reduction in patients cured versus non-responders was 
77%.10  
In the Pakistani population, the hepatitis load is 
approximately between 3-13% of the total 
population.11 After the diagnosis of Hepatitis c 
infection, unfortunately, thinking about diabetes may 
not be 1st issue that comes to mind, both diseases are 
interlinked with each other is an unsolved issue. Their 
co-existence, unfortunately, can speed up the 
dangerous effects of hepatitis C and raised the chances 
of a serious liver injury-related disorder. Insulin 
resistance is known as a warning sign for Hepatitis C 
patients lead to diabetes mellitus disorder. In 
worldwide chronic hepatitis C virus (HCV) infection is 
very high, in 2013 reported population was about 170 
million.12 Decompensated liver cirrhosis together with 
hepatocellular carcinoma due to chronic HCV 
infection is the most common cause of death.13 
Nowadays, chronic HCV infection is considered a 
systemic disease because it does not affect only the 
liver but other organs. Diabetes mellitus is the most 
common extrahepatic manifestations of chronic HCV 
infection.14  
Currently, oral treatment given by the combination of 
Sofosbuvir and Daclatasvir tablets is used to treat 
Hepatitis C infection. Sofosbuvir is the only known 
nucleoside analog that directly binds with the active 
site of polymerase/NS5B15 of hepatitis C virus, so it is 
highly effective against all genotypes and possesses a 
high barrier to resistance. While Daclatasvir is an 
NS5A inhibitor16 effective against all genotypes and 
possesses a low resistance barrier. So, adequate 
combination treatment prefers to overcome this 
resistance. The antiviral therapy response was 
measured by sensitive HCV-PCR testing having low 
detection limits up to < 15 IU / ml in a patient.17  
The primary goal of chronic HCV infection treatment 
is achieved after the sustained viral response (SVR), 
characterized by complete negativity of the hepatitis C 
virus from the patient’s body. SVR is associated with 
decreased liver disease and mortality rate together 
with all-cause mortality rate.18 Diabetic is defined if 
the patient has fasting plasma glucose levels equal to 
or more than 126 mg/dl in three consecutive 
results.19 If PCR shows the negative result at treatment 
end known as End Treatment Response (ETR) while 
after 12 weeks of therapy completion known as 
Sustained Virological Response (SVR).20 
Internationally, SVR is known as the finishing point 
for anti-viral therapy against Hepatitis C patients.21 
The HCV positive genome is composed of single-
stranded RNA approximately 9600 nucleotides with a 
single open reading frame flanked by 5- and 3-
untranslated regions. The 5-UTR contains six 
secondary structure domains termed stem-loops (SLs) 
I–VI. SLII, SLIII, and SLIV form internal ribosome 
entry site that facilitates the translation of cap-less 
HCV RNA.22 
The 5-UTR contains essential replication signals for -
ve RNA, 3-UTR highly conserved and essential for 
HCV replication process.23-25 
HCV belongs in the Flaviviridae family, enveloped 
virus encompasses single, + ve RNA stranded with 9.6 
kb lengthy set of polyproteins up to 3,010 amino acids, 
[26] polyprotein precursors are co- or post translated 
processed by cellular and viral proteases to produce 
functional structural and non-structural proteins.27 The 
structural proteins consist of core protein, C, and 
envelope glycoproteins E1 and E2, non-structural 
proteins included protease NS2, multifunctional 
protein NS3 having serine protease and helicase 
enzyme, serine protease cofactor NS4A, proteins NS4B 
and NS5A, and RNA-dependent RNA polymerase 
NS5B form complex which is responsible for HCV 
replication.28 
Hepatitis C virus enters a susceptible host either 
directly, through needle inoculation or transfusion of 
contaminated blood products, or inadvertently 
through breakage of a percutaneous barrier (as 
exemplified by sexual or perinatal transmission) 
29.virus enters in the hepatocytes or other susceptible 
cells through the viral receptor.30 Total 3% world’s 
population approximately 180 million affected with 
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HCV, Egypt (22%), Pakistan (4.8%), and china (3.2%) 
(31).  
 
Materials and Methods 
 
In this study different items used such as gloves, 
disposable syringes, forceps, spirit cotton swab, simple 
cotton swab, EDTA vials, scissor, Test tubes, 
tourniquet, Test tube stands, ultracentrifuge, Specimen 
containers, test tube holder, cuvettes, serological tubes 
(6.6*50 mm, kimbleno. 45060), pipettes tips (supply), 
micropipettes (Medilines) ρ-Nitrophenyl phosphate, ρ-
nitrophenol, inorganic phosphate, Ρ-NPP., 
oxoglutarate, L-Aspartate, GOT, glutamate, 
oxaloacetate, NADH, MDH, malate, NAD, heparin, 
ETDA, diazotized sulfanilic acid, sulfanilic acid, azo-
bilirubin, drugs reagents, physiological saline(0.9%), 
sodium hydro-oxide and phosphate buffer. 
PCR Machine (Thermocycler), laboratory centrifuge 
(Xinge Scientific Instruments Co.ltd), Coulter mixer 
(LH70), Albumin analyzer(Hi-Med), laboratory 
refrigerator freezer (HSE services), Spectrophotometer 
(Pyrocell), Environmental chamber (Zinis 
laboratories), Humidifier, Hematology analyser (Hi-
Med), Vortex mixer (Lab mixer) (Analytical supplies) 
and Micro-plate centrifuge (Hi-Med). 
It was a cross-sectional comparative research work 
done at Al-Rauf Medical & Surgical Hospital Sargodha 
Region from January to June 2018. In this study total, 
100 patients were chronic hepatitis C disease positive, 
aged 18 years and above with positive HCV RNA 
selected. The exclusion criteria were patients with 
decompensated liver disease and child pug score >12, 
pregnancy, HIV or HBV co-infection, and renal 
dysfunction with Creatinine clearance <50 mL 
/minute. All patients have treated with Sofosbuvir 
and Daclatasvir combination for 12 weeks. 
Sofosbuvir's given dose was 400 mg daily, while 
Daclatasvir given dose was given 60mg daily 
according to the recommended dose and duration of 
oral antiviral therapy. 
The selected people were divided into two groups 
containing 50 patients per group. 1st patients group 
included those patients which have Hepatitis C plus 
diabetes mellitus and named as group A while 2nd 
group included those patients which have Hepatitis C 
without diabetes mellitus and named as group B. Bio-
data included patients age, sex, weight, prior 
interferon therapy,  haemoglobin (Hb) level, Alanine 
aminotransferase (ALT)  level, and bilirubin 
concentration noted. The changes in biochemical and 
haematological parameters were checked at 4 weeks of 
therapy. The serum HCV-RNA testing was performed 
at the end of 12 weeks and to see for ETR and SVR-12 
respectively. 
Tests were performed with a serum sample which is 
taken after centrifugation(7500rpm) for 15 min. The 
serum level of ALP was determined by the 
spectrophotometric method also using an alkaline 
phosphatase kit (Tietz.,1986). Serum bilirubin (total, 
direct and indirect bilirubin), and other parameters 
were measured by appropriate analytical methods 
using the spectrophotometer method for accurate 
results (Kaplan, 1984). Hemoglobin estimation was 
done by Sahil’s method, Estimation of ALT was done 
by Fortress diagnostic kit, Estimation of Alkaline 
Phosphatase, and serum total bilirubin was done by 
Fortress diagnostic kit. The statistical relation of the 
mentioned variables was analyzed through SPSS 
version 15.  
Results 
 
There was a total of 100 patients with mean age 44.24 ± 
11.20 years, weight range was 38 to 113 kg with a 
mean value of 73.35 + 13.00 kg. The mean values of 
baseline Hb, ALT, and bilirubin were 13.04 + 1.68 
g/dl, 82.04 + 66.27 IU/ml, respectively (Table 1). 
 




Min Max Mean + SD 
Age (Years) 19 75 44.24 + 11.20 
Weight (Kg) 38 113 73.35 + 13.00 
Baseline Hb (g/dl) 8.9 17.3 13.04 + 1.68 
Baseline ALT (IU/L) 12 623 82.02 + 66.27 
Baseline Bilirubin 
(mg/dl) 
0.2 4.6 0.98 + 0.66 
Hb at week 4 of 
therapy (g/dl) 
6.5 16 11.77 + 1.79 
ALT at week 4 of 
therapy (IU/L) 
11 122 26.56 + 15.58 
Serum Bilirubin at 
week 4 of therapy 
(mg/dl) 
0.1 5.5 0.92 + 0.59 
(n = 100) 
 
Out of the total of 100 patients, 46% (46) were males 
and 54% (54) were females while 44% (44) patients 
have a history of prior interferon therapy, 23% (23) 
patients were anemic before starting antiviral therapy 
(Table 2). 
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 Table 2: Qualitative variables (n = 100). 
Variables 
/Categories 






Gender   
Male 23 (46%) 23 (46%) 46 (46%) 
Female 27 (54%) 27 (54%) 54 (54%) 
H/O Interferon therapy 
Yes 22 (44%) 22 (44%) 44 (44%) 
No 28 (56%) 28 (56%) 56 (56%) 
ALT normalization during the first month of 
therapy 
Yes 45 (90%) 45 (90%) 90 (90%) 
No 5 (10%) 5 (10%) 10 (10%) 
Baseline Hb 
Normal 38 (76%) 39 (78%) 77 (77%) 
Low 12 (24%) 11 (22%) 23 (23%) 
 
50 patients in each group A and B completed oral anti-
hepatitis C therapy having and not having diabetes 
mellitus respectively. The ETR was achieved in 47 % in 
group A while in the B group it was noted 48% 
without showing any significant variation of results. 
The SVR also did not show any significant difference 
in results in group A & group B of the patients and 
was noted 93% in both groups A & B irrespective of 
being or not being diabetic. The equality of group A 
therapy with group B was observed in statistical 
figures. No decline in Hb> 2g/dl during the first 
month of therapy (p=0.799), ALT normalization 
during the first month of therapy (p=1.000), and no 
rise in serum bilirubin during the first month of 
therapy (p=0.817) were seen not significantly in both 
groups of patients. A decrease in Hb> 2g/dl during 
the first month of therapy was seen in only 9% of both 
groups and hence showed similar results to each other 
in terms of anemia. Similarly, ALT normalization 
during the first month of therapy was seen in 90% of 
individuals of both the groups of the patients. The 
serum bilirubin became elevated than normal value 
during the first month of therapy in only 7% of both 





Table 3: Comparison of response to therapy as well 















ETR     
Achieved 47 (94%) 48 
(96%) 

























Decrease in Hb> 2g/dl during first month of therapy 










2.388) No 40 (80%) 41 
(82%) 
81 
ALT normalization during first month of therapy 










3.694) No 5 (10%) 5 
(10%) 
10 























All trials done on oral antiviral therapy i.e. 
Sofosbuvir/ Daclatasvir against hepatitis C patients 
showed both ETR and SVR above 90%. Hence now the 
same combination is recommended in all HCV 
genotypes. In our study, ETR was achieved excellently 
in group A and group B of patients i.e. 94% and 96% 
respectively. Along with SVR which was also almost 
equally good with the said oral antiviral therapy in 
both diabetic as well as non-diabetic group individuals 
with very minimal difference (i.e. 92% in group A and 
94% in group B patients). This suggests the same 
potency of oral antiviral therapy i.e. Sofosbuvir/ 
Daclatasvir therapy of 12 weeks duration in our 
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population and there was no significant difference 
between diabetic and non-diabetic hepatitis C infected 
patient groups (p-value=0.696 with 95% confidence 
interval). 
Similarly, ALT normalization during the first month of 
therapy was seen the same in patients treated with 
Sofosbuvir/ Daclatasvir oral antiviral regimen in 
groups A and B (90% each). In our study, only two 
parameters were compared in two different groups of 
patients. The patients receiving oral treatment of both 
groups suffered a decrease in Hb> 2 g/dl during the 
first month of therapy though to a very minimal extent 
but almost equally i.e. 20% and 18% in group A and 
group B subjects respectively. Similarly, both A and B 
groups had an equal rise in serum bilirubin levels 
during the first month of therapy (8% versus 6%). 
Hence a very few patients suffered hemolytic anemia 
due to the said oral treatment of hepatitis C infected 
patients whether diabetic or non-diabetic. This whole 
scenario was suggestive that Sofosbuvir/ Daclatasvir 
therapy oral anti-viral treatment was equally 
efficacious for group A and B patients irrespective of 
having or not having diabetes mellites and had fewer 




This study concluded that Sofosbuvir/ Daclatasvir 
tablets oral course of antiviral therapy against hepatitis 
C infected patients for 12 weeks showed excellent 
results, beneficial for the patients suffering from 
diabetes mellitus along with hepatitis C infection as 
compared with antiviral therapy for hepatitis C 
infected patients without diabetes. The concept of co-
existence of hepatitis c plus diabetes which told that 
individuals containing one of them are more prone 
and similarly vanishing HCV infection lowers the risks 
of diabetes; achievement of SVR lead to drop 
prevalence of Diabetes Mellites in patients with 
chronic HCV infection shortly. Insulin resistance leads 
to a worse therapeutic response against insulin 
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